| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 2, 2011
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for...
-
Nov 1, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its partner, PharmaForce/Luitpold Pharmaceuticals, received final approval for Epinastine HCl...
-
Oct 27, 2011-- Fiscal first quarter revenue from continuing operations increased $84 million, or 13%, to a record $725 million
Perrigo Company (Nasdaq: PRGO; TASE: PRGO) today announced results for its first quarter ended September 24, 2011. Perrigo's Chairman and CEO Joseph...
-
Oct 26, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on December...
-
Oct 19, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has entered into a supply agreement with Founder Pharma Co., Ltd., a wholly owned...
-
Oct 18, 2011
Perrigo Company (Nasdaq: PRGO; TASE: PRGO) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug...
-
Oct 14, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal 2012 on Thursday, October 27,...
-
Oct 6, 2011
Perrigo Company (Nasdaq: PRGO;TASE) announced that it received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated...
-
Oct 4, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown and Senior Management will meet with analysts on Wednesday, October 5,...
-
Sep 23, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa and Senior Management will meet with analysts on...